Drug-related infectious diseases - DRID annual expert meeting

Introduction and welcome

Isabelle Giraudon
Dagmar Hedrich, Eleni Kalamara, Julian Vicente, Roland Simon

EMCDDA DRID Key indicator expert meeting – 6-8 June 2016
DRID Key indicator and DRID meeting

• Welcome
  • new nominated experts
  • invited experts
  • experts from Candidate, Potential Candidate Countries and ENP
  • WHO and ECDC

• Purpose of this session
  • to give an overview of the EMCDDA activities
  • to present the agenda and planned products
  • to share updates on country developments
DRID activities – where they fit

• Contribution to the EMCDDA 2016-18 strategy and 2016 work programme*

• …existing expert networks will continue their role as alert-platforms for early warnings in the field of drug-related harm and related responses (infections, deaths and other acute problems).

• …support for the mid-term assessment of the 2013–20 EU drug strategy and the assessment of its first action plan (AP) for 2013–16.

• DRID: an important component of our monitoring of harm – prevalence, notifications, behavioural studies - and of our functions of assessment, early warning, and analysis of the responses in place

Outputs of the DRID work

- Annual update on trends and developments
- European drug report and statistical bulletin
- DRID meeting web pages
DRID projects and progresses since last year

- New ‘Workbooks’ - annual structured national data reporting on Harm and Harm reduction
- ‘Insights’ publication on HCV treatment - World Hepatitis Day
- 2017 ‘Lisbon Addictions conference’
European and global collaborations

- **DG Sante projects**
  - HA-REACT (Joint Action)
  - HepCare (EU funded project)

- **ECDC**
  - Joint report on HIV among PWID (within the Dublin reporting)
  - Joint assessments
  - Joint guidance (PWID, communicable diseases in prison)

- **WHO**
  - Advisory board of the EU Action Plans HCV and on HIV/AIDS
Highlights

• 2016 national DRID updates

• Early warning and threat assessment
  • Outbreaks and incidents
  • Follow-up on HIV multi-indicator risk assessments
Highlights

- Situation, trend analysis and responses
  - HIV and hepatitis prevalence
  - HCV treatment: global framework and local practicalities
  - Injection risk
  - Responses: progresses but also barriers and challenges
  - Assessment of the implementation of the indicator
  - Chemsex: size/relevance of the problem, responses
  - TDI and DRID: using data on testing and sharing
Conclusions

• We wish you a useful and interesting DRID meeting
• Please enjoy the networking opportunities

• Thanks in advance for your feedback

• Contacts: lsabelle.giraudon@emecdda.europa.eu